INmune Bio, Inc. (NASDAQ:INMB) Receives Consensus Rating of “Buy” from Analysts

INmune Bio, Inc. (NASDAQ:INMB) has received a consensus recommendation of “Buy” from the six ratings firms that are covering the company, Marketbeat.com reports. Five analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $22.80.

A number of equities research analysts have issued reports on INMB shares. Maxim Group boosted their price target on INmune Bio from $22.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. RODMAN&RENSHAW upgraded shares of INmune Bio to a “strong-buy” rating in a research report on Tuesday, January 28th. Rodman & Renshaw began coverage on shares of INmune Bio in a research report on Tuesday, January 28th. They issued a “buy” rating and a $23.00 price target on the stock. Finally, Scotiabank boosted their price objective on shares of INmune Bio from $22.00 to $23.00 and gave the company a “sector outperform” rating in a research report on Tuesday, February 11th.

Hedge Funds Weigh In On INmune Bio

Hedge funds have recently modified their holdings of the company. Two Sigma Advisers LP bought a new stake in shares of INmune Bio during the 4th quarter valued at $59,000. Two Sigma Investments LP raised its holdings in INmune Bio by 444.8% during the fourth quarter. Two Sigma Investments LP now owns 66,384 shares of the company’s stock valued at $310,000 after acquiring an additional 54,200 shares during the period. Millennium Management LLC lifted its position in shares of INmune Bio by 43.9% in the fourth quarter. Millennium Management LLC now owns 291,327 shares of the company’s stock valued at $1,360,000 after acquiring an additional 88,823 shares in the last quarter. Laird Norton Wetherby Trust Company LLC lifted its position in shares of INmune Bio by 3.8% in the fourth quarter. Laird Norton Wetherby Trust Company LLC now owns 34,100 shares of the company’s stock valued at $159,000 after acquiring an additional 1,250 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of INmune Bio by 15.2% in the fourth quarter. Bank of America Corp DE now owns 30,449 shares of the company’s stock worth $142,000 after acquiring an additional 4,015 shares during the period. 12.72% of the stock is currently owned by institutional investors.

INmune Bio Price Performance

Shares of INMB opened at $8.02 on Monday. The firm has a market capitalization of $177.82 million, a P/E ratio of -3.68 and a beta of 1.93. INmune Bio has a one year low of $4.32 and a one year high of $12.96. The business has a fifty day moving average of $7.67 and a 200 day moving average of $6.22.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.